Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Specificité
This affinity-purified antibody is directed against the phosphorylated form of Human Smad3 protein at the pSer423 and pSer425 residues. The product was affinity purified from monospecific antiserum by Immunoaffinity purification. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against Human Smad3 pSer423 and pSer425 protein and the antibody is specific for the phosphorylated form of the protein. Reactivity with non-phosphorylated human Smad3 is minimal by ELISA and western blot. Expect reactivity against phosphorylated Smad1 and Smad5. Negligible reactivity is seen against other phosphorylated Smad family members.
Purification
Immunoaffinity Chromatography.
Immunogène
Synthetic peptide corresponding to amino acids 417-425 of Human SMAD3 protein
SMAD3
Reactivité: Humain, Souris, Rat
WB, IHC (p), FACS, IF (cc)
Hôte: Lapin
Monoclonal
3D1
unconjugated
Indications d'application
Suitable for use in ELISA, Immunohistochemistry and Western blot. Expect a bandapproximately 48 kDa in size corresponding to phosphorylated Smad3 protein by Westernblotting in the appropriate stimulated tissue or cell lysate or extract. Less than 0.2%reactivity is observed against the non-phosphorylated form of the immunizing peptide. This antibody is phospho specific for dual phosphorylated pS423 and pS425 of Smad3. Stimulation with 2 ng/ml TGF-beta for 1 hour is suggested. Recommended Dilutions: ELISA: 1/75,000-1/300,000. Western Blot: 1/2,000-1/20,000. Immunohistochemistry: 1/500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
anticorps HSPC193, anticorps HsT17436, anticorps JV15-2, anticorps LDS1C, anticorps LDS3, anticorps MADH3, anticorps madh3, anticorps madh3a, anticorps smad3, anticorps wu:fa99e03, anticorps XSmad3, anticorps XenMLP, anticorps Xmad3, anticorps madh3-A, anticorps Madh3, anticorps AU022421, anticorps Smad 3, anticorps mad3, anticorps madh3b, anticorps zgc:92234, anticorps SMAD family member 3, anticorps SMAD family member 3a, anticorps SMAD family member 3 L homeolog, anticorps SMAD family member 3b, anticorps SMAD3, anticorps smad3a, anticorps smad3.L, anticorps Smad3, anticorps smad3b
Sujet
Smad3 (also known as Mothers against decapentaplegic homolog 3 Mothers against DPP homolog 3, Mad3, hMAD-3, JV15-2 or hSMAD3) is a transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinase. These activators exert diverse effects on a wide array of cellular processes. The Smad proteins mediate much of the signaling responses induced by the TGF-beta superfamily. Briefly, activated type I receptor phosphorylates receptor-activated Smads (R-Smads) at their c-terminal two extreme serines in the SSXS motif, e.g. Smad2 and Smad3 proteins in the TGF-beta pathway, or Smad1, Smad5 or Smad8 in the BMP pathway. Then the phosphorylated RSmad translocated into nucleus, where they regulate transcription of target genes. Based on microarray and animal model experiments, Smad3 accounts for at least 80% of all TGF-beta- mediated response. Alternate names: JV15-2, MAD homolog 3, MAD-3, MADH3, Mad3, Mothers against DPP homolog 3, Mothers against decapentaplegic homolog 3, SMAD 3, SMAD family member 3, SMAD-3